Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext

In a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19, shortening in the duration of viral shedding and hospital stay was observed in patients receiving combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days. Early triple antiviral therapy was found to be safe and superior.

Tags: , ,